ALK and non-small cell lung carcinoma: The results from especially the KEYNOTE-189-trial (KN-189) and KEYNOTE-024, (KN-024), demonstrated that introduction of immunotherapy as a 1L-therapy could have a positive effect on long term survival for non-squamous NSCLC patients without sensitizing EGFR-mutations or ALK-translocations (11, 12).